Evolution of Coronary Stents: From Bare-Metal Stents to Fully Biodegradable, Drug-Eluting Stents by unknown
REVIEW
Evolution of Coronary Stents: From Bare-Metal Stents
to Fully Biodegradable, Drug-Eluting Stents
Jason Foerst • Marc Vorpahl • Michael Engelhardt • Till Koehler • Klaus Tiroch • Rainer Wessely
To view enhanced content go to www.combitherapy-open.com
Received: July 19, 2013 / Published online: December 11, 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
ABSTRACT
Coronary stenting represents the standard of
care for percutaneous revascularization of
symptomatic coronary artery disease. However,
despite progress in the evolution of intravascular
stents, clinical adverse events such as restenosis
and stent thrombosis still represent the ‘‘achilles
heel’’ of this ground-breaking technology. Of
particular note was the association of these
adverse events with the material, the polymer
coating, and the active drug of currently
approved drug eluting stents. Consequently,
modifications were made to the design,
coating, and the choice of drugs, eventually,
resulting in (fully) biodegradable drug-eluting
stents. Such stents offer the appealing concept of
a temporary vascular scaffold and are currently
under extensive preclinical and clinical
investigation. However, biodegradable stents
must demonstrate efficacy and safety in larger
randomized clinical trials in real-world
scenarios, which are currently on the horizon.
Keywords: Biodegradable polymer; Cardiology;
Combination products; Drug-eluting stent;
Pathology; Restenosis; Thrombosis
INTRODUCTION
The introduction of vascular stenting was a
milestone in the field of interventional
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cardiology [1]. The vascular scaffolding
provided by coronary stents significantly
reduced the incidence of acute vessel
occlusions after dissection and restenosis by
vascular recoil as compared with plain old
balloon angioplasty (POBA) [2, 3]. This
dramatic improvement in the percutaneous
treatment of coronary artery disease resulted
in their widespread use in daily practice [4, 5].
Unfortunately, similar to POBA, bare-metal
stents (BMS) were associated with excessive
neointimal formation as a response to
procedure-related wound healing in upto
30–40% of cases [6–8]. Findings from autopsy
studies showed that vascular healing after stent
implantation is similar to wound healing,
including platelet adhesion, fibrin deposition,
and a focal inflammatory cellular infiltrate. This
early process of vascular healing is followed by
re-endothelialization and smooth muscle cell
(SMC) migration and then by proliferation and
matrix formation that can lead to excessive
intimal hyperplasia and clinical restenosis
typically within 3–6 months after stent
implantation [9, 10], or even later.
Drug-eluting stents (DESs) were introduced
as a means of reducing excessive SMC
proliferation. These devices release anti-
proliferative drugs, thus leading to a
significant reduction of neointimal formation
and consequently adverse clinical events like
target lesion revascularization (TLR) and
angiographic restenosis. Enthusiasm for DES
grew quickly following the positive results of
initial large randomized controlled trials
comparing both sirolimus and paclitaxel DES
with their BMS counterparts [11, 12]. However,
early enthusiasm was tempered following
clinical reports of late DES thrombosis [13, 14].
Pathology findings of delayed arterial healing,
hypersensitivity reactions, and malapposition
by vascular remodeling in DES raised concerns
about the impact of the anti-proliferative drugs
and the polymer that is critical for the
modulation of local drug delivery [15, 16].
Given these safety concerns, second-
generation DESs were introduced using cobalt
chromium platforms and modified cell-cycle
inhibitors (everolimus and zotarolimus)
combined with more biocompatible polymers.
When compared with first-generation DES,
these stents proved to be more deliverable
while clinically non-inferior with improved
rates of stent thrombosis [17–24].
Despite the dramatic improvement from
POBA to second-generation DES, there is still
room for further reduction in adverse clinical
events. The majority of adverse events (e.g., acute
recoil, subacute closure, and dissection) occur
early following POBA with very stable long-term
lumen areas beyond a few months [25].
Therefore, perhaps the future of vascular
scaffolding may be stents that can prevent the
early complications of POBA and bioabsorb over
time to allow the vessel to regain its natural shape
and function while eventually improving rates of
stent thrombosis and restenosis by minimizing
late vascular inflammation, hyperproliferation,
and induction of neoatherosclerosis.
Bare-Metal Stents
BMS were designed as a vascular scaffold to treat
POBA-related dissections and acute vessel
occlusions, and to reduce vascular recoil. Early
BMS were made of 316 L stainless steel, nitinol
wire coils, or nitinol coils with various designs
and were self- or balloon expandable [7].
Lessons from autopsies showed that vascular
healing following intravascular BMS
implantation is very similar to the response
after wound healing [10]. The initial stage
(\30 days) includes platelet adhesion, mild
luminal thrombus formation, fibrin
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deposition, and a focal inflammatory cellular
infiltrate consisting of polymorphonuclear
leukocytes and macrophages. T-lymphocyte
infiltration starts around 2 weeks and persists
for several months. The early process of vascular
healing (2–4 weeks) is followed by SMC
migration, proliferation, and matrix formation
(proteoglycans/collagen type III). Completion
of vascular repair in humans is usually achieved
by re-endothelialization 3–4 months after BMS
implantation. Neointimal formation peaks at
6–12 months, with a neointimal volume
decrease by replacement of collagen III with
collagen I [10]. In about 30–40% of cases the
SMC activation leads to an untoward excessive
intimal hyperplasia, which may result in
clinically relevant restenosis and need for
repeat revascularization [26].
First-Generation DES
While BMS were a dramatic leap forward in
the arsenal of interventional cardiologists, the
30–40% rate of clinically relevant restenosis
prompted the development of DES to inhibit
neointimal hyperplasia and SMC
proliferation. Permanent polymer coatings
were applied to control the release kinetics
of the anti-proliferative drug that acts to
minimize neointimal growth. The sirolimus-
eluting stents (SES) used polyethylene-co-
vinyl (PEVA) and poly n-butyl methacrylate
(PBMA) as a non-erodible polymer releasing
80% of the drug sirolimus (140 mg/cm2) from
the BxVelocityTM (Cordis, Johnson &
Johnson, Miami, FL, USA) BMS backbone
within the first month. The various
generations of paclitaxel-eluting stent (PES)
(originally on NIR BMS backbone and
subsequently Express and then Liberte
backbones) had a slow release polymer with
8.8% drug to polymer ratio (1 lg/mm2). The
moderate release version with three times the
local drug concentration was studied in the
TAXUS II trial, with improved rates of target
lesion revascularization, but was not released
commercially [27].
Early DES versus BMS trials demonstrated
DES superiority with significantly reduced rates
of TLR and angiographic restenosis to \10% in
the RAVEL trial [11], the SIRIUS trials [28–31],
and the TAXUS trials [12, 32–34].
Consequently, both first-generation DES, the
SES (Cypher, Cordis, Johnson & Johnson,
Miami, FL USA), and the PES (Taxus, Boston
Scientific, Natick, MA USA) were rapidly
approved by the regulatory bodies in Europe
and the USA in 2002/2003.
Following the success of initial clinical trials
of first-generation DES, the indications rapidly
expanded to complex lesions [35] like chronic
total occlusion [36] and left main disease [37].
However, the initial enthusiasm was tempered
by clinical case reports and preliminary data
from the large Swedish Coronary Angiography
and Angioplasty Register (SCAAR), and other
groups [13, 14], showing a significant increase
in late stent thrombosis (LST) in DES.
Concomitantly, autopsy studies revealed that
delayed arterial healing and impaired re-
endothelialization were strongly associated
with the frequently fatal LST [38]. Pathologic
findings showed the development of unstable
features like neoatherosclerosis within the
neointima as a frequent finding in first-
generation DES, which may partly contribute
to events of lLST [15]. Of note, clinical cases of
very LST were reported up to 4 years after the
initial implantation of first-generation DES.
These safety concerns led to a remarkable
reduction of DES usage in 2007. Clinicians
began to prescribe dual anti-platelet therapy
for 1 year or longer to avoid LST. Around this
time the US Food and Drug Administration
Comb Prod Ther (2013) 3:9–24 11
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(FDA) demanded that all DES manufacturers
support the ongoing DAPT trial [39] in an
effort to determine the optimal duration of
dual anti-platelet therapy for DES.
Interestingly, the 5-year follow-up of the
SCAAR results did not suggest a long-term
significant increase of LST in DES as compared
with BMS [40].
Second-Generation DES
The first-generation DESs were another leap
forward compared with BMS; however, there
was still concern about LST and reduced
deliverability with the 140 lm strut/polymer
thickness. The second-generation DESs were
designed to overcome these flaws using for
example thinner cobalt chromium alloys, new
cell-cycle inhibitors (everolimus/zotarolimus),
and more biocompatible polymers
(fluoropolymers/phosphorylcholine). Whereas
the first-generation DES continued to release
drug for a prolonged duration, the release
kinetics of the second-generation DES was
generally shorter.
The Xience V (Abbott Vascular, CA, USA)
everolimus-eluting stent (EES) is also marketed
by Boston Scientific as PROMUS (Everolimus-
Eluting Platinum Chromium Coronary Stent
System) and is composed of a poly-vinylidene
fluoride and hexafluoropropylene (PVDF–HFP)
polymer that is loaded with everolimus at a
concentration of 1 lg/mm2. EES release 80% of
everolimus within 1 month and 100% release
within 4 months after implantation. The
clinical trial program included the SPIRIT I
[17], SPIRIT II [19], SPIRIT III [18], and SPIRIT
IV trials [20] the open-label SPIRIT V registry
[41], and the all comer COMPARE trial [42].
These studies consistently exhibited low major
adverse cardiac event (MACE) rates, target vessel
failure, and definite or probable stent
thrombosis with the EES as compared with
first-generation DES (PES).
Biocompatibility is largely considered
secondary to the hydrophilic nature of stent
polymers, as measured by lower contact angles
(the angle between liquid/blood versus solid/
stent), in vitro. The contact angles of the various
DES are as follows: PC (Endeavor, Medtronic
Vascular, Santa Rosa, CA, USA) 83, BioLinxTM
(Resolute, Medtronic, Santa Rosa, CA, USA) 94,
PBMA (Cypher) 115, SIBS (Taxus) 118 and
fluoropolymer (Xience) 129. In vitro studies
demonstrate that the more hydrophilic, the less
macrocyte adhesion occur relative to other DES
platforms [43]. Rabbit models confirmed these
findings with the Endeavor stents
demonstrating the lowest inflammation and
fibrin scores at 30 days [44]. The Endeavor
zotarolimus-eluting stent (ZES) was well
studied in the ENDEAVOR [23], ENDEAVOR II
[21], ENDEAVOR III [24], SORT OUT III [45], and
ZEST [46] trials, and in the E-FIVE registry [47],
which confirmed consistently low MACE rates
and target vessel failure. Notably, LST was rare
compared with the first-generation DES (PES,
SES). The Resolute ZES has a novel
biocompatible hydrophilic polymer, termed
BioLinx, that combines the biocompatible
nature of the Endeavor stent with a
hydrophobic core to allow for prolonged drug
elution and improved long-term reductions in
neointimal hyperplasia. The Resolute stent has
50% and 85% drug release at 7 and 60 days after
stent implantation, respectively, versus the
Endeavor, with 75% drug release at 2 days. This
effect is correlated clinically with TLR rates of
12% of the Resolute versus 16% in the Endeavor
group at 2 years [48].
The so-called ‘third-generation’ Promus
Element (Boston Scientific, Natick, MA, USA)
DES has the same polymer and drug elution
properties as the Promus/Xience EES, with a
12 Comb Prod Ther (2013) 3:9–24
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new platinum alloy to improve fluoroscopic
visibility. The stent backbone is designed for
improved deliverability by removing some of
the interconnectors, though this may be related
to reports of longitudinal compression both
clinically and in bench-top models relative to
other DES [49, 50]. The clinical outcomes of the
Promus Element versus the Xience V stents were
comparable up to 3 years in the PLATINUM
studies [51]. Due to concerns about longitudinal
compression, the stent has since been altered to
allow for more support on the proximal and
distal crowns.
While being generally considered
biocompatible, the polymer coating of the
first- and second-generation DES prevents
them from truly behaving like BMS, after time,
even after all of the drug is eluted. Reports of
hypersensitivity reactions and positive vascular
remodeling resulting in stent strut
malapposition in those DES have raised
concerns that the permanent polymer
implants may be linked to late DES thrombosis
[15]. Other pathologic studies of BMS and DES
have implicated alloyed stents themselves in
chronic inflammation, angiogenesis,
neoatherosclerosis [52], restenosis, obstruction
of side branches, and LST via stent fracture [15].
Therefore, the concept of a biodegradable
polymer coating or fully biodegradable
vascular scaffolds remains appealing as a
means of mitigating these late stent/polymer-
vessel interactions.
Biodegradable Polymer Implementation
in the Vascular Scaffold Stent
Various biodegradable polymers have been
used since the 1960s for orthopedic, dental,
and wound closure applications. The ideal
bioabsorbable polymer should demonstrate
no toxic or inflammatory responses, should
be readily metabolized, easy to produce, and
have a good shelf life as well as homogenous
application properties [53]. Polymer
biodegradation is generally a hydrolytic
process starting with the penetration of water
into the polymer. The hydrolysis of ester
bonds between repeating lactide units
fragments the long polymer chain into
multiple products including lactic acid,
glycolic acid, and finally water and carbon
dioxide [54]. Polyacidic acid copolymers such
as polylactic acid (PLA, 6 months degradation
time) or polyglycolic acid (PGA, 2–3 months
degradation time) are commonly used in
current biodegradable vascular stents [55].
The time course of degradation itself depends
on various factors including the chemical
bond, the pH, the presence of catalysts, and
the co-polymer composition. Stent polymer
coatings are prone to mechanical damage
during the fabrication process as well as the
deployment procedure. The clinical impact of
uneven polymer distribution, flaking or
webbing remains poorly understood [56]
(Fig. 1).
Clinical Impact of Biodegradable Polymer
Coated Stents
DESs with completely biodegradable polymer
coatings were designed with the goal of early
neointimal hyperplasia inhibition, followed by
polymer absorption, with the hope of minimal
long-term inflammatory responses similar to
the BMS vascular interaction. Preclinical
histopathologic analysis of porcine implanted
biodegradable polymer (PLA and PGA) SES
demonstrated a reduction of neointimal
formation and a reduced cellular inflammatory
response when compared with permanent
polymer SES and BMS at 28, 90, and 180 days
post-implantation [57]. Similar results were seen
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in the NoboriTM biolimus-eluting stent
(Terumo, Tokyo, Japan) as compared WITH a
permanent polymer SES [58] and the stainless
steel sirolimus releasing Combo stent
(OrbusNeich, Wanchai, Hong Kong) with a
biodegradable SimBioSYS coating and anti-
CD34 antibody coating in a porcine model
[59] (Fig.2).
Following the non-inferiority 1-year results
of the EVOLVE trial, the SYNERGY (Boston
Scientific, Natick, USA) stent with an abluminal
everolimus releasing PLGA polymer coating was
Fig. 1 Representative SEM images from the enzymatic
digested stents deployed into the coronary arteries of pigs
for 7 days. a–c The polymer coating of the BioMatrix stent
displayed polymer cracking within the inner curvature and
linker bards (white arrow head); d–f the polymer coating of
the Cypher SELECT displayed uneven coating (white
arrows) with small-round defects (dashed circle); g–i the
TAXUS Liberte´ polymer coating displayed webbing
(dashed arrow), uneven coating (white arrow), and focal
regions of bare metal exposure (black arrow head); j–l the
XIENCE V polymer coating displayed regions of uneven
coating (white arrow) and polymer ﬂaking (black arrow).
(white bar 200 lm; red bar 30 lm). Reproduced with
permission from [56]
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CE marked in October, 2012. The EVOLVE II
trial was designed with the goal of approval
within the US and Japanese markets and
enrolled the first patient in November 2012.
The trial compared the SYNERGY stent with the
Promus Element Plus platinum chromium stent
with a primary endpoint of 12-month target
lesion failure defined as any ischemia-driven
revascularization of the target lesion,
myocardial infarction (MI; Q-wave and non-Q-
wave) related to the target vessel, or cardiac
death.
The EXCELLA BD randomized clinical trial
with the DESyneTM BD Novolimus-Eluting
Coronary Stent System, Elixir Medical
Corporate, Sunnyvale, CA, USA, with
resorbable polymer demonstrated superior
results compared to the Endeavor stent for the
primary endpoint of in-stent late lumen loss
[60]. The LEADERS trial demonstrated that a
biodegradable polymer-based biolimus eluting
stent (BioMatrix FlexTM, Biosensors, Biosensors
International, Tokyo, Japan) was non-inferior to
permanent polymer SES at 1 year. Another
biolimus-eluting degradable PLA polymer stent
(Nobori, Terumo; 6–9 month degradation time)
was evaluated in the COMPARE II and NOBORI
trials, demonstrating clinical non-inferiority
versus EES at 1 year [61]. Contrarily, the large
(1,229 patient) SORT OUT V trial compared the
biodegradable polymer lated biolimus-eluting
stent (Nobori) with permanent polymer SES and
found that at 9 months the rate of cardiac
death, MI and definite stent thrombosis or
Fig. 2 Representative histomorphometric images at 14 and 28 days in Cypher, Combo, LD-Combo and Genous stent.
Reproduced with permission from [59]
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target vessel revascularization (TVR) was 4.1%
for the Nobori versus 3.1% (P = 0.22) for the
permanent polymer SES [62]. Interestingly, the
difference was largely driven by the stent
thrombosis endpoint of 0.7% for the biolimus-
eluting stent versus 0.2% for the SES
(P = 0.034). Likewise, the PLGA PES in the
CoSTAR II trial demonstrated an unexpected
clinical inferiority compared with the PES
control stent [63]. Long-term data derived
from the ISAR-TEST 4 trial found similar 3-year
rates of TLR, target vessel re-infarction and
cardiac death while numerically (though not
statistically significant) less definite stent
thrombosis with a custom-made biodegradable
polymer SES versus permanent polymer SES/EES
[64].
Numerous other iterations of biodegradable
polymer-coated stents are currently on the
clinical trial horizon, including the sirolimus-
eluting Biolute stent with a PLA or PLGA
polymer Orsiro stent (Biotronik, Berlin,
Germany [65]), the Excel stent (JW Medical
Systems, Shandong, China [66]), and the
Coracto stent (Alvimedica, Istanbul, Turkey
[67]).
Completely Biodegradable Stents
The ultimate evolution of coronary stents is
complete bioabsorption following lesion
treatment with return of normal endothelial
function while maintaining long-term patency.
Igaki and Tamai pioneered the development of
a completely biodegradable polymeric stent
(poly-L-lactic acid [PLLA] polymer) (Igaki–
Tamai stent, Kyoto Medical Planning Co. Ltd,
Kyoto, Japan) with 170 lm strut thickness and
24% stent strut surface/vessel coverage that is
both self-expanding and balloon expandable.
They reported the first in-man series in 2000
after 25 stents were implanted in 15 patients.
Initial 6-month angiographic and intravascular
ultrasound (IVUS) follow-up demonstrated
acceptable rates of restenosis and TVR (6.7%:
1/15 patients) with no deaths or MI [68]. The
long-term follow-up ([10 years) of 50 patients
reported lack of significant stent recoil and
negative vessel remodeling, but with a 50%
MACE rate and two cases of a definite stent
scaffold thrombosis [69].
This concept was adopted and further
developed into the drug-eluting bioresorbable
vascular scaffold (BVS) program of Abbott
Vascular (Abbott Vascular, Santa Clara, CA,
USA). Their BVS PLLA back-bone provides
radial force while a poly-D,L-lactic acid
(PDLLA) coating controls the release of
everolimus. Both the PLLA and PDLLA are
fully biodegradable leaving only small
platinum markers at the scaffold edges. In
order to keep the mechanical strength of a
conventional stent, strut thickness was almost
doubled to 150 lm, which may negatively
impact stent deliverability [70, 71]. Preclinical
studies evaluated the fully biodegradable stents
in porcine coronary arteries implanted for
1 month and up to 3 years demonstrating non-
inferior rates of neointima formation and
vascular inflammation in comparison with
permanent polymer SES. The degradation of
the polymer was evident within 2 years.
Histopathology exhibits replacement of struts
with a proteoglycan matrix [16, 72] (Fig. 3).
The first in-man ABSORB I (Cohort A) trial
was a prospective, open-label study that
enrolled 30 patients who had either stable,
unstable, or silent ischemia and a single de-
novo lesion (Type B1 and B2) that was suitable
for treatment with a single 3.0 9 12 mm or
3.0 9 18 mm stent. At 5 years, there were no
events of ischemia-driven TLR or cardiac death
[73]. Two-year follow-up with optical coherence
tomography (OCT) revealed fully bioabsorbed
16 Comb Prod Ther (2013) 3:9–24
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stents with late lumen loss of 10% and restored
vasomotion [74]. Improvements of scaffold
design and a modified manufacturing process
of its polymer led to the second iteration of the
trial (ABSORB I: Cohort B). Again, imaging
studies with IVUS or OCT were performed at
various intervals up to 36 months in 101
patients. There was 100% device deployment
success with slightly more complex lesions than
the Cohort A. Two-year results were comparable
to the SPIRIT trial data with the original Xience
V stent with no cardiac deaths, 3% non-Q-wave
MI, and 6% ischemia-driving percutaneous
coronary intervention with no scaffold
thrombosis [75–77]. The ABSORB EXTEND
trial is an ongoing non-randomized, single
Fig. 3 a–d Representative histological sections of a Bioab-
sorbable Vascular Solutions (BVS) stent in pig coronary
arteries removed at 1, 18, 24, and 36 months (EVG
staining); e–h High-power images of strut regions (H&E)
showing presence of ﬁbrin at 1 month and absence at all
other time points. Empty spaces represent BVS struts up to
24 months; i and j Smooth muscle actin positive cells are
observed in the neointima and media at 1 and 36 months,
respectively; k–m Representative images of a 36-month
BVS. Note the strut outline is barely visible. k Illustrates
complete degradation of the polymer strut with surround-
ing basophilic deposition of calcium (H&E). l Alcian blue
positive proteoglycan (blue) inﬁltrated the matrix of the
BVS stent strut. m Calciﬁcation is seen around the
degraded stent strut (von Kossa). Reproduced with
permission from [72]
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arm, continued access trial allowing greater
complexity of lesions with planned
overlapping allowed in longer (22–28 mm)
lesions and a greater variety of stent lengths
and diameters. The ABSORB II trial is a
European randomized trial against the Xience
Prime looking at co-endpoints of vasomotion
(change in minimal luminal diameter [MLD]
before and after nitroglycerine and change in
MLD at 2 years versus post-procedure). The
ABSORB III trial started in early 2013 and is
the first randomized trial in the US comparing
the BVS against Xience DES with a primary
endpoint of target lesion failure at 1 year. The
duration of dual anti-platelet therapy in these
trials remains 1 year and, given the increased
strut thickness, may be more important than
with current generation DES.
A different concept was initiated by
Biotronik who introduced the first metallic
bioabsorbable magnesium stent (AMS) with a
strut thickness of 165 lm and 10% vessel
coverage (comparable to current metallic
stents) with no drug coating. The prospective,
non-randomized, multicenter clinical trial,
DREAMS (Drug Eluting Absorbable Metal
Scaffold), demonstrated impressive
angiographic results immediately after stent
implantation [78]. However, accelerated
absorption of the stent resulted in early loss of
Table 1 Pros and cons of fully absorbable DES
PRO CON Unanswered questions
Need orientated temporary scaffold Cost Optimal material/design
No indeﬁnite foreign body Limited radial force of the scaffold Optimal time frame of degradation
No need for long-term DAPT Bulky design limits application Pathobiological long-term effects
(inﬂammation, neoatherosclerosis,
calciﬁcation)
Sufﬁcient drug carrier Lesion/implantation limitations
Potential for fracture
Table 2 Biodegradable polymer-coated drug-eluting stents
Stent Company Polymer Drug
OrsiroTM Biotronik Biolute Sirolimus
NOYATM Med favor PDLLA Sirolimus
FirehawkTM MicroPort PDLLA Sirolimus
AXXessTM Biosensors PLA Biolimus
BiomatrixTM Biosensors PLA Biolimus
ComboTM OrbusNeich PLA Sirolimus







NoboriTM Terumo PLA Biolimus
BuMATM SinoMed PLGA Sirolimus
CoractoTM Alvimedica PLGA Sirolimus













InspironTM Sctech PLLA/PLGA Sirolimus
18 Comb Prod Ther (2013) 3:9–24
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the structural integrity of the scaffold and radial
force within weeks. Consequently, initial
clinical trials in the periphery and coronary
circulation suggested higher rates of restenosis
when compared with traditional BMS [79, 80].
The REVA stent (REVA Medical, Inc., San
Diego, CA, USA) is made of a tyrosine-derived
polycarbonate polymer (poly[deaminotyrosyl-
tyrosine ethyl ester] carbonate) and is radio-
opaque due to the incorporation of iodine
molecules. The stent is balloon expandable,
strut thickness is 200 lm, stent coverage 55% of
the vessel and designed with a unique slide and
lock (ratchet) mechanism. The first in-man
RESTORE pilot study I (Pilot Study of the
ReZolve REVA Medical, Inc. San Diego, CA
USA Sirolimus-Eluting Bioresorbable Coronary
Scaffold) analyzed outcomes of 22 patients
implanted between December, 2011 and July,
2012 and found a preliminary late lumen loss of
0.2 mm comparable to DES studies [81]. The
ReZolve2 trial is underway with the next-
generation REVA bioabsorbable stent with
improved radial strength and deliverability.
Determination of the most efficient radial
strength and optimal degradation time are
still under extensive preclinical and clinical
investigations (Table 1). Drug-eluting
balloons that leave no scaffolding have
demonstrated promising results for in-stent
restenosis [82] and will need to be compared
with bioabsorbable stent outcomes. A
comprehensive list of investigational
bioabsorbable polymer coated stents/fully
bioabsorbable stents and current fully
bioabsorbable stent trials is listed in Tables 2,
3 and 4.
CONCLUSION
While the current generation DESs have
dramatically improved the rates of adverse
events in clinical practice, the ongoing quest
to minimize late stent thrombotic events while
maintaining maximal lumen diameters and
retuning normal vessel physiology is ongoing.
The biodegradable polymers and completely
biodegradable stents represent the ‘‘cutting
Table 3 Completely biodegradable stents
Stent Company Polymer Drug
BVSTM Abbott P(D)LLA Everolimus
AMS-4.0TM Biotronik PLLA Sirolimus
ReZolveTM REVA Medical Poly (DTE carbonate) Paclitaxel
IDEALTM Xenogenics PAE and salicylic acid Sirolimus
On-ABSTM OrbusNeich PLLA/PCL/PDLLA Sirolimus
BTITM Bioabsorbable therapeutics Polymer/salicylate ? linker Sirolimus
DeSolveTM Elixir Medical PLLA Novolimus/Myoli
ART Arterial Remodeling Technologies PLLA n/a
Amaranth Amaranth Med. PLLA n/a
Xinsorb Huaan Biotech PLLA Sirolimus
Acute Orbus Neich Poly-L-lactic, poly-D-lactic, and
poly-L-lactide-co-e caprolactone
Sirolimus
Comb Prod Ther (2013) 3:9–24 19
123
edge’’ in the evolution of DES technology. As
substantiated by early clinical trials, these stents
achieve temporary vessel scaffolding to obtain
optimal vessel calibers, prevent vessel recoil,
and stabilize dissections until the vessel has
healed. Through their bioabsorption, normal
vessel physiology and vasomotion return over
time. However, the clinical experience of
currently available ‘‘bulky’’ and expensive
biodegradable stents is limited to a total of
\10,000 estimated implanted stents worldwide.
Dual anti-platelet duration is not reduced and
may be required for a longer time given the
thicker stent struts with bioabsorbable stents.
Several important features such as optimal
polymer composition, degradation, drug release
kinetics, impact of neoatherosclerosis, and stent
fracture are the focus of current investigations
(Table 1). Likewise, ongoing ‘‘real world’’
clinical experience is needed to gain better
evidence after promising initial results.
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